RNA-seq of human aortic smooth muscle cells treated with recombinant sST2 and angiotensin II

To elucidate the mechanism by which sST2 contributes to aortic disease, human aortic smooth muscle cells were exposed to recombinant sST2 and angiotensin II. Cells were allocated to two 24-hour treatment groups(n = 3): angiotensin II alone or the combination of recombinant sST2 plus angiotensin II, followed by RNA-seq analysis.

为阐明可溶性ST2（sST2）参与主动脉疾病的作用机制，本研究将人主动脉平滑肌细胞暴露于重组可溶性ST2与血管紧张素II（angiotensin II）中。将细胞分为两组（每组n=3），分别接受24小时处理：仅施加血管紧张素II，或联合施加重组可溶性ST2与血管紧张素II，随后进行RNA测序（RNA-seq）分析。